NEW YORK, January 14, 2026, 05:10 (EST) — Premarket
- Beyond Air shares slip in premarket following a steep rally on Tuesday
- The move follows XTL’s deal to acquire an 85% stake in Beyond Air’s NeuroNOS unit
- Traders are focused on whether the rally can maintain momentum when regular trading kicks off
Shares of Beyond Air, Inc. plunged 16.4% to $1.83 in premarket action Wednesday, following a wild 150% surge that closed Tuesday at $2.19. The stock swung between $1.37 and $2.66 during Tuesday’s session, with volume skyrocketing to roughly 408.6 million shares—far above the three-month average of 6.76 million. 1
The swing matters now because Beyond Air is a small stock and the new headline changes what investors think they own. The deal ties Beyond Air’s narrative to another listed company’s shares and introduces a slew of “if-then” payments that could quickly pull in short-term money.
That setup often leads to a noisy tape. Heavy volume attracts buyers, yet it also hands early traders a clear exit to lock in profits.
XTL Biopharmaceuticals announced it has inked a binding deal to buy 85% of NeuroNOS Ltd., a subsidiary of Beyond Air that develops drug candidates targeting autism spectrum disorder and neuro-oncology. In return, Beyond Air will take a 19.9% stake in XTL and receive up to $32.5 million in cash and milestone payments, including an initial $1 million cash payment, the companies said. The milestones break down to as much as $5.5 million linked to clinical development and up to $26 million tied to sales achievements. 2
Beyond Air Chief Executive Steve Lisi described the deal as a “pivotal moment” for NeuroNOS, highlighting its potential to generate shareholder value. XTL CEO Noam Band noted that the acquisition marks XTL’s entry into autism drug development.
The companies noted that NeuroNOS holds FDA orphan drug designations for both Phelan‑McDermid Syndrome and glioblastoma. This orphan status in the U.S. targets rare diseases and offers perks like a market exclusivity period upon approval.
Beyond Air’s main focus remains its LungFit PH nitric oxide delivery system, designed for newborns suffering from hypoxic respiratory failure. The company also confirmed it’s working on additional nitric oxide-based projects. With the NeuroNOS deal, Beyond Air retains a minority stake in that unit and gains a substantial shareholding in XTL.
However, the cash beyond the initial payment hinges on hitting milestones. Those payments rely on clinical progress, regulatory approvals, and eventual sales — all factors that can drag on for years or might never come through.
Investors will be watching closely for more clarity on closing conditions and any additional disclosures in the coming days. Given the stock just moved about 60 times its normal volume, any next surprise is likely to come from the capital-raising front.
At 09:30 a.m. EST, the market opens fully, bringing back liquidity. Traders will then weigh if Tuesday’s surge marks a real turnaround or merely a brief spike.
